BioCryst制药盘中异动 股价大涨5.05%
北京时间2025年01月03日01时13分，BioCryst制药（BCRX.us）股票出现波动，股价急速拉升5.05%。截至发稿，该股报7.90美元/股，成交量64.3707万股，换手率0.31%，振幅5.52%。
最近的财报数据显示，该股实现营业收入1.17亿美元，净利润-14.03百万美元，每股收益-0.07美元，毛利1.14亿美元，市盈率-12.94倍。
机构评级方面，在所有11家参与评级的机构中，91%的券商给予买入建议，9%的券商给予持有建议，无券商给予卖出建议。
BioCryst制药股票所在的生物技术行业中，整体涨幅为0.68%。其相关个股中，Revelation Biosciences Inc C/Wts 10/01/2027 (To Pur Com)、Klotho Neurosciences Inc C/Wts 21/06/2029 (To Pur Com)、Nrx Pharmaceuticals Inc C/Wts 24/05/2026 (To Pur Com)涨幅较大，Revelation Biosciences, Inc.、Mustang Bio, Inc.、知临集团较为活跃，换手率分别为1197.40%、284.07%、206.22%，振幅较大的相关个股有Revelation Biosciences Inc C/Wts 10/01/2027 (To Pur Com)、Mustang Bio, Inc.、Revelation Biosciences, Inc.，振幅分别为170.00%、146.61%、136.01%。
BioCryst制药公司简介：BioCryst Pharmaceuticals Inc 是一家生物技术公司，主要从事新型小分子药物的研究和开发，以阻断感染和炎症疾病的关键酶。Biocryst的研究基于多种科学学科，如生物学、计算机建模和药物化学。其产品和候选产品针对以下治疗领域——急性无并发症流感、无并发症的季节性流感、遗传性血管性水肿、丝状病毒包括埃博拉病毒和马尔堡病毒、和肿瘤。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10